In a significant advancement for inpatient diabetes care, Glooko has secured US Food and Drug Administration (FDA) clearance for its EndoTool IV Cloud platform. This milestone marks the evolution of a long-standing clinical tool into a modern, scalable, cloud-based infrastructure designed to meet the growing demands of hospital systems worldwide. By transitioning from traditional on-premise software to a cloud-based delivery model, Glooko aims to streamline the delivery of personalized insulin dosing for critically ill patients, setting a new benchmark for efficiency and precision in intensive care settings.
The Evolution of Clinical Precision: Understanding EndoTool IV Cloud
The EndoTool system has served as a bedrock for intravenous (IV) insulin therapy since its initial FDA clearance in 2006. Originally developed by Monarch Medical Technologies, the system provides real-time, algorithmic support for clinicians managing complex glucose regulation in hospitalized patients. Following Glooko’s strategic acquisition of Monarch in September 2025, the company began integrating its robust data ecosystem with Monarch’s specialized clinical software.
The new "EndoTool IV Cloud" retains the exact, proven core insulin dosing algorithms that have historically helped clinicians minimize the risks of hyperglycemia and hypoglycemia. However, the architecture of the system has been fundamentally overhauled. By moving to the cloud, the platform eliminates the heavy reliance on localized, resource-intensive server infrastructure that has historically plagued hospital IT departments.
Key Technical Improvements:
- Enhanced Scalability: Hospital networks can now deploy the tool across multiple wards or entire healthcare systems without the need for complex, site-specific hardware installations.
- Reduced IT Burden: Cloud deployment simplifies software maintenance, security updates, and performance monitoring, allowing hospital staff to focus on patient outcomes rather than technical upkeep.
- Seamless Integration: The cloud-native approach allows for more agile integration with Electronic Health Records (EHRs) and other digital health platforms within the Glooko ecosystem.
A Chronology of Growth: Glooko’s Strategic Expansion
Glooko’s journey toward the launch of EndoTool IV Cloud is the result of a deliberate, multi-year strategy focused on horizontal and vertical integration within the diabetes management space.
- November 2024 – Series F Financing: Glooko secured $100 million in a Series F funding round. This massive injection of capital was earmarked specifically for international market expansion, with a particular focus on the Middle East and Asia, where the prevalence of diabetes is rising at an alarming rate.
- Early 2025 – The Hedia Partnership: Glooko partnered with Danish digital therapeutics firm Hedia to bring advanced bolus insulin dosing support to the UK market, signaling the company’s commitment to supporting patients both inside and outside the hospital.
- Mid-2025 – The Monarch Acquisition: The acquisition of Monarch Medical Technologies provided Glooko with the clinical "crown jewel" of inpatient care—the EndoTool. This move bridged the gap between outpatient monitoring and critical care intervention.
- Late 2025 – Ecosystem Expansion: Glooko continued to broaden its platform’s utility by integrating with major continuous glucose monitoring (CGM) systems, most notably Abbott’s FreeStyle Libre, reaching an estimated 4.5 million users worldwide.
- May 2026 – FDA Clearance: The culmination of these efforts, the FDA clearance of EndoTool IV Cloud, positions Glooko as the dominant player in both the consumer and clinical diabetes technology markets.
Supporting Data: The Rising Tide of Diabetes
The necessity for Glooko’s latest innovation is underlined by sobering statistics from the International Diabetes Federation (IDF). The global diabetes population is currently on a trajectory to reach 643 million individuals by 2030.
As the prevalence of diabetes rises, so too does the burden on hospital systems. A significant percentage of patients admitted for non-diabetes-related issues—such as surgery, infection, or trauma—present with comorbid hyperglycemia. Managing these patients in an ICU or surgical setting requires precise insulin titration to avoid the dangers of erratic blood glucose levels, which are linked to longer hospital stays, increased infection rates, and higher mortality.
By digitizing and automating these protocols via the cloud, Glooko is not just selling software; it is providing a scalable solution to a global public health crisis. The scalability of the cloud-based system allows hospitals to provide a standardized level of high-quality care to a larger volume of patients, regardless of the hospital’s size or geographic location.
Official Responses and Clinical Perspectives
The industry has reacted with optimism to the FDA announcement, viewing it as a logical next step in the "digitization of the bedside."
Paul Chidester, Medical Director of EndoTool at Glooko, emphasized that the transition to the cloud does not compromise the clinical integrity of the product. "With EndoTool IV Cloud, we are preserving the same trusted clinical foundation and insulin dosing algorithm while making the solution easier to deploy, maintain, and scale for hospital teams," Chidester noted.
For clinicians, the "trust factor" is paramount. Transitioning to a cloud environment often raises concerns about latency and reliability. Glooko has addressed these by maintaining the underlying mathematical rigor that clinicians have relied on for nearly two decades, ensuring that the transition is an improvement in delivery rather than a change in clinical methodology.
Implications for the Healthcare Ecosystem
The implications of this move extend far beyond Glooko’s corporate growth; they signal a fundamental shift in how hospitals manage chronic diseases in acute settings.
1. The Death of the Silo
Historically, hospital software was fragmented, with proprietary systems locked into specific hardware. By moving to the cloud, Glooko is encouraging a shift toward interoperability. If the insulin management tool is cloud-based, it can theoretically "talk" to other cloud-based medical systems, creating a unified dashboard for patient health that spans from the patient’s home (via their personal Glooko app) to the hospital bed (via EndoTool IV Cloud).
2. Standardization of Care
Variability in clinical practice is a major cause of poor patient outcomes. When different hospitals use different, often manual, methods for insulin titration, patient care can become inconsistent. Glooko’s cloud-based platform promotes standardization. By offering a uniform, evidence-based algorithm across different hospital systems, the company is helping to raise the "floor" of clinical care, ensuring that a patient in a small community hospital receives the same algorithmic precision as a patient in a top-tier research center.
3. Economic Impact
For hospital administrators, the cloud-based model offers a more predictable cost structure. By reducing the need for on-premise IT maintenance and hardware lifecycle management, hospitals can lower their operational expenses (OPEX). Furthermore, by potentially reducing the length of hospital stays through better glucose control, the system offers a high return on investment (ROI) that is increasingly attractive to cost-conscious healthcare providers.
Looking Ahead: The Commercialization Phase
As Glooko prepares for the commercial launch of EndoTool IV Cloud in the United States by the end of 2026, the company is also looking toward international markets. The scalability of the cloud allows for rapid deployment in regions with developing healthcare infrastructure, provided the necessary local regulatory hurdles are cleared.
The company’s roadmap for the remainder of 2026 suggests a focus on seamless integration. As Glooko continues to grow its roster of over 200 integrated devices, the EndoTool IV Cloud will likely become the "central nervous system" for inpatient diabetes care.
In conclusion, the FDA clearance of EndoTool IV Cloud represents a maturation of digital health. It proves that the future of medical technology is not just in the development of new algorithms, but in the intelligent deployment of existing, proven clinical knowledge. As Glooko positions itself at the intersection of consumer diabetes management and critical hospital care, it is clear that the company is building a comprehensive ecosystem that addresses the needs of patients, clinicians, and hospital systems in equal measure. With the diabetes population growing, the arrival of this scalable, cloud-native tool could not be more timely.
About the Author
